Evaluation of efficacy and safety of autologous bone marrow mesenchymal stem cells for traumatic spinal cord injury: Use-results comparative survey
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 612
- 主要终点
- Percentage of the case with 1 or more levels of AIS improvement
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- No limit 至 No limit(—)
- 性别
- All
入选标准
- •(1) Patients using autologous mesenchymal stem cells derived from bone marrow for the first time for traumatic spinal cord injury
- •(2) Patients or their surrogates must provide informed consent before the start
排除标准
- 未提供
结局指标
主要结局
Percentage of the case with 1 or more levels of AIS improvement
时间窗: from 6-8 weeks (49 +/- 7 days) to 180 days +/- 30 days after injury
Percentage of the case with 1 or more levels of AIS improvement from 6-8 weeks (49 +/- 7 days) to 180 days +/- 30 days after injury in **AIS B or C patients aged 20 to 70 years with traumatic cervial spinal cord injury**
Percentage of the case with 2 or more levels of AIS improvement
时间窗: from 6-8 weeks (49 +/- 7 days) to 180 days +/- 30 days after injury
Percentage of the case with 2 or more levels of AIS improvement from 6-8 weeks (49 +/- 7 days) to 180 days +/- 30 days after injury in **AIS A patients aged 20 to 70 years with traumatic cervial spinal cord injury**
次要结局
未报告次要终点
